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Randomized Comparisons T2T vs. RC. In the STREAM [1] trial, a T2T arm aimed at REM (DAS<1.6), with consecutive step-up therapy including MTX and ADA, and the control arm consisted of traditional DMARDs (no prednisone or biologics were allowed). After a follow-up of 24 months, DAS, DAS remission and HAQ change showed no significant differences between the groups, and also median SHS increase did not differ between the treatment arms (T2T 0 (IQR 0-1.1] and RC: 0.5 (IQR 0-2.5)).
The "Twin target" steered arm of a Japanese trial [2] aimed at reaching DAS28<2.6
as well as normalization of serum matrix metalloproteinase 3 (MMP3). This strategy was compared with two other treatment-targeted arms, one steering at DAS28< 2.6, the other at MMP3 normalization alone. The fourth arm consisted of a routine therapy control group. After a follow-up of 56 weeks, significantly more patients in the Twin group had attained the treatment target (56%) than in the routine control group or in the MMP3 group.
T2T SLR update -Supplementary File Version 1 Furthermore, the T2T concept was confirmed in the IDEA study, a double-blind randomized controlled trial with 112 treatment-naïve RA patients comparing the efficacy of methotrexate and infliximab with methotrexate and intravenous corticosteroid for remission induction [3] .
Non-randomized studies. In a non-controlled prospective cohort study (DREAM [4] ),
T2T proved successful: patients with very early RA received target-oriented treatment aiming at remission (DAS28<2.6). After 6 months, 47% achieved the target, 58% good EULAR response and the median time to first DAS28<2.6 was 25.3
weeks (IQR13.0-52.0). After 12 months, 58% achieved the treatment target, 68%
good EULAR response, and there was no clinically relevant radiographic progression in a majority of patients.
Comparing the DREAM cohort with a RC cohort of 2 early RA inception cohorts, [5] the authors found that after 1 year, 55% (T2T) versus 30% (RC) of the patients were at DAS28<2.6, and median time to its first achievement was 25 weeks (T2T) vs. >52 weeks (RC) (p<0.0001). Furthermore, there was a significant difference in DAS28 change -2.5 (T2T) vs. -1.5 (RC) (p<0.0001).
Similarly, [6] comparing the DMARD arms of the BeSt study (N=234) to routine treatment in 2 ERA clinics (N=201) showed significantly better outcomes after 1 year in patients receiving T2T. HAQ improvement was 0.7 vs. 0.5 (p = 0.029), 31% vs.
18% of patients had DAS28 <2.6 (p<0.005) and median SHS progression was 2.0 (with an expected progression of 7.0) vs. 1.0 (expected progression 4.4); however, as the authors state, the BeSt cohort had longer median disease duration (0.5 vs 0.4 years, p = 0.016), higher mean DAS28 (6.1 vs 5.7, p<0.001), more rheumatoid factor-positive patients (66% vs 42%, p<0.001), and more patients with pre-existing erosions (71% vs 53%, p<0.001).
In a comparison of early RA patients included in the GUEPARD trial, a T2T-trial aiming at low disease activity (DAS28ESR<3.2), with routine care patients of the ESPOIR cohort, [7] T2T led to higher percentages of patients characterised as "remission including functional remission (HAQ <0.5) and absence of radiological progression" (32.3% vs 10.2%, p=0.011). Also, more patients in the T2T regime were classified as having "low DAS and HAQ <0.5 and absence of radiological progression" (36.1% vs 18.9%, p=0.045), and more T2T patients had HAQ<0.5
(70.2% vs 45.2%, p=0.005). There was no difference in DAS decrease and EULAR, T2T SLR update -Supplementary File Version 1 ACR responses, and the mean SHS progression was similar in the two groups as was the percentage of patients without progression.
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